761 related articles for article (PubMed ID: 37143162)
21. Barriers and facilitators to implementing medications for opioid use disorder and naloxone distribution in Veterans Affairs emergency departments.
Sasson C; Dieujuste N; Klocko R; Basrai Z; Celedon M; Hsiao J; Himstreet J; Hoffman J; Pfaff C; Malmstrom R; Smith J; Holstein A; Johnson-Koenke R
Acad Emerg Med; 2023 Apr; 30(4):289-298. PubMed ID: 36757683
[TBL] [Abstract][Full Text] [Related]
22. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
23. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
24. Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.
Frost MC; Richards JE; Blosnich JR; Hawkins EJ; Tsui JI; Edelman EJ; Williams EC
Drug Alcohol Depend; 2022 Aug; 237():109521. PubMed ID: 35716644
[TBL] [Abstract][Full Text] [Related]
25. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
Dowd WN; Barch DH; Seibert JH; Mark TL
J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
[TBL] [Abstract][Full Text] [Related]
27. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine.
Brunet N; Moore DT; Lendvai Wischik D; Mattocks KM; Rosen MI
Subst Abus; 2022; 43(1):39-46. PubMed ID: 32078492
[No Abstract] [Full Text] [Related]
28. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
[TBL] [Abstract][Full Text] [Related]
29. The cost of opioid use disorder-related conditions in Medicare.
Mark TL; Parish WJ; Weber EM; Steinberg DG; Henretty K
Drug Alcohol Depend; 2023 Mar; 244():109778. PubMed ID: 36701935
[TBL] [Abstract][Full Text] [Related]
30. Primary care experiences of veterans with opioid use disorder in the Veterans Health Administration.
Jones AL; Kertesz SG; Hausmann LRM; Mor MK; Suo Y; Pettey WBP; Schaefer JH; Gundlapalli AV; Gordon AJ
J Subst Abuse Treat; 2020 Jun; 113():107996. PubMed ID: 32359670
[TBL] [Abstract][Full Text] [Related]
31. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
J Gen Intern Med; 2024 Apr; ():. PubMed ID: 38587730
[TBL] [Abstract][Full Text] [Related]
32. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
[TBL] [Abstract][Full Text] [Related]
33. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
34. What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings.
Hooker SA; Sherman MD; Lonergan-Cullum M; Nissly T; Levy R
J Subst Abuse Treat; 2022 Oct; 141():108804. PubMed ID: 35643586
[TBL] [Abstract][Full Text] [Related]
35. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
36. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities.
Hagedorn HJ; Gustavson AM; Ackland PE; Bangerter A; Bounthavong M; Clothier B; Harris AHS; Kenny ME; Noorbaloochi S; Salameh HA; Gordon AJ
J Gen Intern Med; 2022 Nov; 37(14):3594-3602. PubMed ID: 34981352
[TBL] [Abstract][Full Text] [Related]
37. Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness.
Tarn DM; Shih KJ; Ober AJ; Hunter SB; Watkins KE; Martinez J; Montero A; McCreary M; Leamon I; Sheehe J; Bromley E
Community Ment Health J; 2023 Feb; 59(2):345-356. PubMed ID: 35906435
[TBL] [Abstract][Full Text] [Related]
38. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
39. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
[TBL] [Abstract][Full Text] [Related]
40. Association of Early Opioid Withdrawal Treatment Strategy and Patient-Directed Discharge Among Hospitalized Patients with Opioid Use Disorder.
Alrawashdeh M; Rhee C; Klompas M; Larochelle MR; Poland RE; Guy JS; Kimmel SD
J Gen Intern Med; 2023 Aug; 38(10):2289-2297. PubMed ID: 36788169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
